Editorial Volume 11, Issue 2 pp 291—292

Hormone therapy outcome in lymphedema

Figure 1. Tamoxifen treatment leads to lymphatic dysfunction and aggravates lymphedema. Tamoxifen inhibits estrogen binding to its receptor ERα on lymphatic endothelial cells to block both genomic and non-genomic pathways. After long-term delivery, the blockade of ERα by hormone therapy leads to lymphatic dilatation and leakage, the main features of lymphatic shape in lymphedema.